Two years after treatment, both girls show normal motor function and no signs of spinal muscular atrophy symptoms.

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.

Steven Levine, MD: Carrie, can you talk about what’s involved in procuring intranasal esketamine [Spravato], the various routes, whether that’s buy-and-bill or specialty pharmacy, and any of the ...

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

Those complexities extend to billing and coding. Sometimes navigating these complexities is a reason for patients who are ...

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...